KURA

Business Context and Reporting Period

This Form 8-K was filed by Kura Oncology, Inc. on October 20, 2015. The report primarily addresses corporate governance updates and business disclosures in anticipation of a proposed public offering.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a pre-IPO biotechnology company, the report focuses on operational milestones rather than historical financial performance.

Material Changes

• Code of Ethics: The Board of Directors adopted a Code of Business Conduct and Ethics on October 20, 2015. This code applies to all directors, officers, and employees and is effective contingent upon the closing of the Company's proposed public offering.
• Business and Risk Updates: The Company filed updated descriptions of its business operations and risk factors to supplement previous SEC filings.

Guidance, Outlook, and Risks

The filing contains extensive forward-looking statements regarding the Company's future prospects. Key areas of uncertainty and risk include:

• The initiation, cost, timing, and results of research and development activities and clinical trials.
• The ability to obtain and maintain regulatory approval for product candidates.
• The ability to attract collaborators and secure intellectual property protection.
• Market acceptance of future products and competition from other drugs.
• The ability to obtain additional financing and manage capital requirements.
• Reliance on third-party suppliers and manufacturers.

Management cautions that actual results may differ materially from expectations due to these risks.

Investor Verification Checklist

• Verify the status and expected closing date of the proposed public offering.
• Review the attached Exhibit 14.1 for the full text of the new Code of Business Conduct and Ethics.
• Examine Exhibit 99.1 for the specific updates to business descriptions and risk factors.
• Confirm the Company's current cash runway and financing needs, as this filing does not disclose specific liquidity figures.